198 related articles for article (PubMed ID: 37889928)
1. Impact of cervical screening by human papillomavirus genotype: Population-based estimations.
Wang J; Elfström KM; Lagheden C; Eklund C; Sundström K; Sparén P; Dillner J
PLoS Med; 2023 Oct; 20(10):e1004304. PubMed ID: 37889928
[TBL] [Abstract][Full Text] [Related]
2. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.
Wheeler CM; Hunt WC; Joste NE; Key CR; Quint WG; Castle PE
J Natl Cancer Inst; 2009 Apr; 101(7):475-87. PubMed ID: 19318628
[TBL] [Abstract][Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
4. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
5. [Changes in genotype prevalence of human papillomavirus over 10-year follow-up of a cervical cancer screening cohort].
Dong L; Hu SY; Zhang Q; Feng RM; Zhang L; Zhao XL; Ma JF; Shi SD; Zhang X; Pan QJ; Zhang WH; Qiao YL; Zhao FH
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jan; 38(1):20-25. PubMed ID: 28100371
[No Abstract] [Full Text] [Related]
6. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study.
Smith MA; Sherrah M; Sultana F; Castle PE; Arbyn M; Gertig D; Caruana M; Wrede CD; Saville M; Canfell K
BMJ; 2022 Mar; 376():e068582. PubMed ID: 35354610
[TBL] [Abstract][Full Text] [Related]
7. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
[TBL] [Abstract][Full Text] [Related]
8. Impact of high-risk Human Papillomavirus genotyping in cervical disease in the Northern region of Portugal: Real-world data from regional cervical cancer screening program.
Rosário A; Sousa A; Marinho-Dias J; Medeiros R; Lobo C; Leça L; Coimbra N; Tavares F; Baldaque I; Martins G; Monteiro P; Henrique R; Sousa H
J Med Virol; 2023 Jan; 95(1):e28414. PubMed ID: 36541747
[TBL] [Abstract][Full Text] [Related]
9. Use of Multiplex Polymerase Chain Reaction for Detection of High-Risk Human Papillomavirus Genotypes in Women Attending Routine Cervical Cancer Screening in Harare.
Marembo T; Dube Mandishora R; Borok M
Intervirology; 2019; 62(2):90-95. PubMed ID: 31412350
[TBL] [Abstract][Full Text] [Related]
10. Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56-60.
Lamin H; Eklund C; Elfström KM; Carlsten-Thor A; Hortlund M; Elfgren K; Törnberg S; Dillner J
BMJ Open; 2017 May; 7(5):e014788. PubMed ID: 28566363
[TBL] [Abstract][Full Text] [Related]
11. The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with L-SIL cytology: A retrospective study of 8726 cases.
Tao X; Zhang H; Zhang H; Xiao Y; Zhong F; Zhou X; Cong Q; Sui L; Zhao C
Cancer Cytopathol; 2022 Jul; 130(7):542-550. PubMed ID: 35312217
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study.
Gori S; Battagello J; Gustinucci D; Campari C; Zorzi M; Frayle H; Passamonti B; Sartori G; Bulletti S; Fodero C; Cesarini E; Faggiano R; Del Mistro A
BJOG; 2021 Jul; 128(8):1353-1362. PubMed ID: 33326680
[TBL] [Abstract][Full Text] [Related]
13. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
14. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
Malagón T; Kulasingam S; Mayrand MH; Ogilvie G; Smith L; Bouchard C; Gotlieb W; Franco EL
Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
[TBL] [Abstract][Full Text] [Related]
15. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results.
Schiffman M; Burk RD; Boyle S; Raine-Bennett T; Katki HA; Gage JC; Wentzensen N; Kornegay JR; Aldrich C; Tam T; Erlich H; Apple R; Befano B; Castle PE
J Clin Microbiol; 2015 Jan; 53(1):52-9. PubMed ID: 25339396
[TBL] [Abstract][Full Text] [Related]
16. Risk stratification for cervical precancer and cancer by DH3-HPV partial genotyping and cytology in women attending cervical screening: A retrospective cohort study.
Fu Y; Li Y; Li X; Wang X; Lü W
J Med Virol; 2023 Feb; 95(2):e28482. PubMed ID: 36609841
[TBL] [Abstract][Full Text] [Related]
17. HIGH-RISK HPV testing as the primary screening method in an organized regional screening program for cervical cancer: the value of HPV16 and HPV18 genotyping?
Kares S; Veijalainen O; Kholová I; Tirkkonen M; Vuento R; Huhtala H; Tuimala V; Mäenpää J; Kujala P
APMIS; 2019 Nov; 127(11):710-716. PubMed ID: 31403733
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the effectiveness of HPV16/18 infection referred for colposcopy in cervical cancer screening in Northwest of China.
Zhang Q; Zhao M; Cao D; Wei X; Wang L; Li Y; Yang T; Zhao J; Pei M; Jia H; Cao S; Quan S; Yang X
J Med Virol; 2018 Jan; 90(1):165-171. PubMed ID: 28710863
[TBL] [Abstract][Full Text] [Related]
19. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus genotype distribution among women with and without cervical cancer: Implication for vaccination and screening in Ghana.
Nartey Y; Amo-Antwi K; Hill PC; Dassah ET; Asmah RH; Nyarko KM; Agambire R; Konney TO; Yarney J; Damale N; Cox B
PLoS One; 2023; 18(1):e0280437. PubMed ID: 36656844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]